MedTrace Logo

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

NCT03936218 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-04-17

No results posted yet for this study

Summary

A two arm, multi centric, randomized, open label, parallel, two doses pharmacodynamics study in patients with advanced prostate cancer.

Conditions

Interventions

DRUG

Inj. Goserelin (Test) Subcutaneously

10.8 mg, subcutaneously at every 3 month

DRUG

Inj. Zoladex (Reference) Subcutaneously

10.8 mg, Subcutaneously at every 3 month

Sponsors & Collaborators

  • Eurofarma Laboratorios S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2023-11-30
Completion
2024-04-01

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03936218 on ClinicalTrials.gov